

CMBI Credit Commentary

Fixed Income Daily Market Update 固定收益部市场日报

- *BNKEA/NANYAN/DAHSIN T2s widened another 5-10bps this morning. CCAMCLs tightened 1-2bps. NWDEVLs were unchanged to 1.0pt lower. VNKRLs up 0.3-0.6pt.*
- *BTSDf: USD24.7mn of BTSDf 13.5 06/26/2026 remains outstanding after tender offer. Initiate buy on the new BTSDf 9.125 07/24/28. BTSDf 26s/28s were largely unchanged this morning. See below.*
- *China will guide big state-owned insurance companies to raise both the size and proportion of their investments in Chinese stocks listed on the mainland and equity funds. Chinese lifers CTIHs/PINGINs/PINGRPs/SUNSHGs moved -0.1 to +0.1pt this morning.*

❖ Trading desk comments 交易平台市场观点

Yesterday, market spotlight remained on properties. Media reported Shenzhen government has recently brought in CICC to conduct due-diligence on Vanke's financial position. Vanke was also reported to be in final stages of negotiations of stakes sales in VX logistics and GLP and the developer expects RMB20bn (USD2.73bn) from both sales to help debt repayments. VNKRL 25-29s fell another 4.1-5.9pts, closed 2.9-8.2pts lower YTD. On the other hand, LNGFOR 27-32s/SHUION 25-26s were up 0.3-0.5pt. In HK, NWDEVL Perps/27-31s declined another 2.4-5.2pts, closed 13.0-27.3pts lower YTD. NANFUN/HYSAN Perps were unchanged to 0.4pt lower on some PB selling. In financials, the new BZLNZ 10NC5 bond tightened 7bps from RO (CT5+130) despite some profit taking. The recent new RCBPM 30s widened 2bps from RO (CT5+115). In T2s, BNKEAs T2s widened 5bps. BBLTB/OCBCSP/ANZ/CBAU/WSTP T2s widened 1-2bps. In EU AT1s, INTNED 7.25/UBS 9.25 Perps were unchanged to 0.3pt higher. Chinese AMCs were firm on onshore buying. CCAMCLs/ORIEASs tightened 5-7bps. CFAMCLs were 0.1-0.4pt higher (3-10bps tighter). In insurance hybrids, DAIL Perp was up 0.1pt, while NIPLIF 54s/MYLIFE 54s/SUMILF Perp were 0.1-0.3pt lower. ALVGR/ZURNVX 53-54s were down 0.1-0.2pt. Chinese IGs were mixed. LENOVOs widened 2bps, while MEITUAs tightened 1-2bps. In India, UPLLIN Perp was up 0.4pt, closed 0.9pt higher WTD. In the Philippines, VLLPM 27s/29s rebounded 0.6-1.1pts.

In LGFVs, the flows gradually slowed down as onshore clients prepared for CNY long holiday, while the space remained skewed to better buying. SHGUOH/QDJZWD 25s were up 0.2pt. There were two-way interest on CNH names such as QZCCGC/ZOUCAO 27s. In SOE perps, CHPWCN Perps were unchanged to 0.1pt higher.

Glenn Ko, CFA 高志和
 (852) 3657 6235
 glennko@cmbi.com.hk

Cyrena Ng, CPA 吳倩瑩
 (852) 3900 0801
 cyrenang@cmbi.com.hk

Jerry Wang 王世超
 (852) 3761 8919
 jerrywang@cmbi.com.hk

❖ Last Trading Day's Top Movers

Top Performers	Price	Change	Top Underperformers	Price	Change
VLLPM 9 3/8 07/29/29	95.2	1.1	VNKRLE 3 1/2 11/12/29	44.7	-5.9
VLLPM 7 1/4 07/20/27	94.3	0.6	NWDEVL 4 1/2 05/19/30	40.2	-5.2
LNGFOR 3.95 09/16/29	69.9	0.5	NWDEVL 3 3/4 01/14/31	40.3	-5.2
UPLIN 5 1/4 Perp	95.2	0.4	NWDEVL 5 7/8 06/16/27	45.9	-5.0
CFAMCI 5 1/2 04/27/47	93.5	0.4	VNKRLE 3.975 11/09/27	46.0	-4.8

❖ Marco News Recap 宏观新闻回顾

Macro – S&P (+0.61%), Dow (+0.30%) and Nasdaq (+1.28%) were strong on Wednesday. Tech stocks up after USD500bn AI infrastructure investment plan from a venture involving Oracle, OpenAI and SoftBank, even though there was no clarity on funding. UST yield moved higher on Wednesday, 2/5/10/30 yield at 4.29%/4.43%/4.60%/4.82%.

❖ Desk Analyst Comments 分析员市场观点

➤ **BTSDf: USD24.7mn of BTSDf 13.5 06/26/2026 remains outstanding after tender offer. Initiate buy on the new BTSDf 9.125 07/24/28**

H&H International (H&H) accepted USD275.3mn in principal amount of BTSDf 13.5 06/26/2026 for purchase at USD109.8 in a tender offer. This is financed by the proceeds from the issuance of BTSDf 9.125 07/24/28 of USD300mn last week. After settlement of the tender offer, USD24.7mn of BTSDf 13.5 06/26/2026 will remain outstanding. The tender offer and concurrent issuance of new bonds effectively lengthen the maturity profile of H&H further while reducing the weighted average interest cost.

Besides, we expect H&H to early redeem the remaining outstanding amount of USD24.7mn of BTSDf 13.5 06/26/2026 with internal resources to reduce the interest cost. As per H&H, its funding cost (incl. hedging costs) was 7.07% in 1H24.

Meanwhile, we initiate buy on BTSDf 9.125 07/24/28 (Ba3/BB/-), in view of H&H's good access to various funding channels, lengthened maturity profile as well as better trading liquidity. Recalled that H&H prepaid USD term loans of USD581mn in Nov'24 which originally due in Jun'25. At 100.6, BTSDf 9.125 07/24/28 is trading at YTM of 8.9%, and offering yield pick-up of 72bps over FOSUNI 8.5 05/19/28 (-/BB/-, YTM of 8.2%), and 140bps over GWFOOD 3.258 10/29/30 (-/BB, YTM of 7.5%) with 2.2 years shorter in maturity.

➤ **Offshore Asia New Issues (Priced)**

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
Gaci First Investment Co/ Public Investment Fund	2,400/1,600	5yr/9.5yr	5.25%/5.625%	5.39%/5.713%	Aa3/-/A+

➤ **Offshore Asia New Issues (Pipeline)**

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
Republic of the Philippines	USD	-	10yr/25yr	T+120/6.1%	Baa2/BBB+/BBB

The Korea Development Bank	USD	-	3yr/5yr	SOFR MS+58/ SOFR MS+77	Aa2/AA/AA-
----------------------------	-----	---	---------	---------------------------	------------

➤ News and market color

- Regarding onshore primary issuances, there were 103 credit bonds issued yesterday with an amount of RMB45bn. As for month-to-date, 1,759 credit bonds were issued with a total amount of RMB1,408bn raised, representing a 44.6% yoy increase
- Indonesia will raise requirement for natural resources export proceeds deposit to 100% from 30% for at least a year. Implementation timeline is not specified
- **[FOSUNI]** Fosuni International's plan to acquire the 40.4% stake in Shanghai Henlius to take it private was rejected by shareholders. Fosun Pharma will continue to be Henlius's controlling shareholder with a 59.6% interest, the planned privatization will not proceed and Henlius's shares will continue to be listed on the Stock Exchange of Hong Kong
- **[HYUELE]** SK Hynix 4Q24 EBITDA triples, revenue rises 75% yoy
- **[NWDEVL]** Media reported PJT Partners seeks to organize NWD bondholders to against loan refinancing
- **[PLNIJ]** Media reported PLN plans to raise offshore bonds up to USD1.5bn, first return to USD bond market after 4 years if realized
- **[SUNAC]** Sunac China said USD717.6mn of aggregate principal of its MCB remain unconverted

[VNKRLE] Media reported Shenzhen government brought in CICC to assess Vanke's financial position

Fixed Income Department

Tel: 852 3657 6235/ 852 3900 0801

fis@cmbi.com.hk

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past

performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial

Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.